ReviewCNS drugs2009
Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.
Review in CNS drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Latrepirdine for Alzheimer's disease.The Cochrane database of systematic reviews · 2015Pooled it
- Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Drugs · 2011Pooled it
- Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.BMC complementary and alternative medicine · 2017Trial
- Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.International journal of medical sciences · 2012Trial
- Nanomedicine: A New Frontier in Alzheimer's Disease Drug Targeting.Central nervous system agents in medicinal chemistry · 2025Review
- The effects of carvacrol and p-cymene on AβCNS neuroscience & therapeutics · 2024Article
- Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.Molecules (Basel, Switzerland) · 2020Review
- Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease.Neural regeneration research · 2019Article
- UHPLC-ESI-ORBITRAP-MS analysis of the native Mapuche medicinal plant palo negro (Leptocarpha rivularis DC. - Asteraceae) and evaluation of its antioxidant and cholinesterase inhibitory properties.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- PROTECTIVE EFFECT OFAfrican journal of traditional, complementary, and alternative medicines : AJTCAM · 2017Article
- Linalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer's mice.Neuropharmacology · 2016Article
- Dementia, Preclinical Studies in Neurodegeneration and its Potential for Translational Medicine in South America.Frontiers in aging neuroscience · 2016Review
- Gene Therapy Models of Alzheimer's Disease and Other Dementias.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Clinical compliance of donepezil in treating Alzheimer's disease in taiwan.American journal of Alzheimer's disease and other dementias · 2015Article
- The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.Neuropharmacology · 2015Article
- Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.The primary care companion for CNS disorders · 2014Review
- sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.ACS chemical neuroscience · 2013Article
- Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.Patient preference and adherence · 2013Article
- Amelioration of amyloid β-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer's disease.CNS neuroscience & therapeutics · 2012Article
- Transdermal donepezil on the treatment of Alzheimer's disease.Neuropsychiatric disease and treatment · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mainstay of current management of patients with Alzheimer's disease involves drugs that provide symptomatic therapy. Research approaches for future therapy of Alzheimer's disease are focusing on disease modifying and/or preventive approaches. Two classes of medications have been approved by the US FDA for the treatment of Alzheimer's disease: the cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine), mostly for mild to moderate Alzheimer's disease, and the noncompetitive NMDA receptor antagonist memantine for the moderate to severe stages of Alzheimer's disease. Management of comorbid medical problems can be more complex in patients with dementia than in those without dementia. Unfortunately, medication adherence in Alzheimer's disease is low and good adherence is essential for attempting to slow disease progression and improve or stabilize quality of life. Simplifying treatment regimens and providing more caregiver- and patient-friendly modes of administration that fit in better with daily routines can ease caregiver stress which, in turn, may have a favourable impact on the patient's condition. To overcome problems of medication adherence in the elderly, simple, user-friendly dosage regimens should be prescribed for all medications; thus the need for novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease, such as once-daily donepezil, memantine and galantamine, and transdermal rivastigmine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.